Oxymetholone in aplastic anaemia

processing.... Drugs & Diseases oxymetholone (Rx) Brand and Other Names: Anadrol-50

  • Classes: Anabolic Steroids
  • Share
  • Email
  • Print
  • Feedback
Close
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
Sections oxymetholone (Rx)
  • Sections oxymetholone
  • Dosing & Uses
  • Interactions
  • Adverse Effects
  • Warnings
  • Pregnancy
  • Pharmacology
  • Images
  • Patient Handout
  • Formulary
Dosing & Uses Adult Pediatric Dosage Forms & Strengths tablet: Schedule III

Professional Services SP Laboratories is a grade Pharmacy with a consolidate value and quality of the product. We are health oriented on worldwide medicine and the best results in patients. Our manufacturing process is based on golden rules that are designed to obtain performance in quality, services, hygiene and final patient consumption. We are very firm convinced that providing highly professional services we give customers the trust and the certainty that SP Laboratories ensures a healthy way of life for patients.

  • Health Our medicines are produced under high production standards and meet all the international rules in medical and sanitary patient protection.
  • Products SP Laboratories has a wide range of medicines, specially produced for general health. We have a high developed technology in order to offer you the most premium medical products.
  • Our Team We have the most qualified specialist that prepare unique medicines under special formulas. We guarantee a high level of production and assembling using the latest laboratory technology.
IMPROVING
THE QUALITY OF LIFE  

At 3 months post-study enrollment, 11 patients in the supportive care group who showed no improvement became eligible and were crossed over to receive Atgam therapy. Efficacy was evaluated as sustained improvement in peripheral blood counts within 3 months of entry into the study. A statistically significant (p<) difference was observed between the two treatment groups in hematological improvement based on the investigator's evaluation; 11 of 21 (52%) patients in the Atgam group responded, compared with no patients (0 of 20) in the control group. Six of the 11 crossover patients from the control group showed improvement after 3 months of therapy. Overall, of 32 patients in both the Atgam group and the control group who crossed over to receive Atgam, 17 patients (53%) had a hematological improvement. Estimated 1-year survival rate was 62% for all 32 patients treated with Atgam. The 2-year survival rate was 100% among the Atgam responders [17 of the 32 patients (53%) compared to 14% for the nonresponders].

Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

  • Blood tests and bone marrow tests to watch for signs of bone marrow failure , leukemia or immune disorders .
  • Regular dentist visits for preventive care and to check the mouth for signs of cancer.
  • Yearly check-up by an ear, nose and throat (ENT) doctor starting at age 10. Children with DKC are at higher risk of cancer of the mouth, tongue or throat.
  • Breathing tests to measure how well their lungs work (pulmonary function tests). We start when your child is old enough to cooperate (usually 6 to 10 years). If there are problems, your child will get care from a lung specialist .
  • Checking their diet and measuring vitamin D levels in the blood to check bone health. Children with DKC are at higher risk of low bone density (osteopenia). If this is a concern, your child will see an endocrinologist .
  • Yearly exams to check for signs of cancer affecting the genitals, starting at age 18 for young women. It is important for both boys and girls to get the vaccine to protect against the human papillomavirus (HPV). HPV can cause cancers affecting the genitals.

Oxymetholone in aplastic anaemia

oxymetholone in aplastic anaemia

Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Media:

oxymetholone in aplastic anaemiaoxymetholone in aplastic anaemiaoxymetholone in aplastic anaemiaoxymetholone in aplastic anaemiaoxymetholone in aplastic anaemia